Spinogenix
Los Angeles, US · Founded 2016 · Delaware corporation
Spinogenix is a biopharmaceutical company developing therapies to restore synaptic function, with a pipeline aimed at neurological and neurodegenerative conditions.
Founders & leadership
Spinogenix was founded in 2016 by Stella Sarraf, Ph.D. and Stella Sarraf.
SS
Stella Sarraf, Ph.D.Co-founder
SS
Stella SarrafCEO, Founder, Director
PV
Peter VanderklishChief Science Officer
SG
Sharron GargoskyChief Development Officer
RM
Ryan MacDonaldChief Business Officer
SD
Sasha Damouni EllisHead of Investor Relations
FH
Franz HeftiNamed on SEC filing
JS
Josh SwartzNamed on SEC filing
Board
SY
Steve YoungBoard director
JL
Jerre L. SteadBoard director
MT
Mervyn Turner, Ph.D.Board director
CE
Craig EricksonChief Medical Advisor
Reported raises · per SEC filings
Form D private placements$24.7M disclosed across 7 rounds · 2017–2025
▶$10.6MraisedMar 2026 · 5 investors · Other Health CareRule 506(b)
▶$10.6MraisedMar 2026 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Steve YoungDirector
- Stella Sarraf, Ph.D.Executive Officer, Director
- Jerre L. SteadDirector
- Mervyn Turner, Ph.D.Director
- Offering amount
- $35M
- Amount sold
- $10.6M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedJun 2024 · 3 investors · Other Health CareRule 506(b)
▶$2.8MraisedJun 2024 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mervyn TurnerDirector
- Dan AlbostaExecutive Officer
- Stella SarrafExecutive Officer, Director
- Peter Whitney VanderklishExecutive Officer
- Jerre SteadDirector
- Offering amount
- $25M
- Amount sold
- $2.8M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedAug 2023 · 3 investors · Other Health CareRule 506(b)
▶$5.2MraisedAug 2023 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Vincent SimmonExecutive Officer, Director
- Stella SarrafExecutive Officer, Director
- Mervyn TurnerDirector
- Peter Whitney VanderklishExecutive Officer
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedSep 2022 · 3 investors · Other Health CareRule 506(b)
▶$3.3MraisedSep 2022 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Peter Whitney VanderklishExecutive Officer
- Vincent SimmonExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Sep 2022
- Incorporated
- Corporation, De
- Federal exemptions
- 06b
▶$1.6MraisedFeb 2021 · 22 investors · Other Health CareRule 506(b)
▶$1.6MraisedFeb 2021 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Franz HeftiDirector
- Vincent SimmonExecutive Officer
- Peter VanderklishExecutive Officer
- Offering amount
- $2.3M
- Amount sold
- $1.6M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedSep 2020 · 12 investors · Other Health CareRule 506(b)
▶$250KraisedSep 2020 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Vincent SimmonExecutive Officer
- Peter Whitney VanderklishExecutive Officer
- Franz HeftiDirector
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$903.3KraisedMay 2018 · 10 investors · Other Health CareRule 506(b)
▶$903.3KraisedMay 2018 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stella SarrafExecutive Officer, Director
- Franz HeftiDirector
- Josh SwartzDirector
- Offering amount
- $903.3K
- Amount sold
- $903.3K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld47 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Biogen Idec31 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Companies competing with Spinogenix for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $314.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Spinogenix do?
- Spinogenix is a biopharmaceutical company developing therapies to restore synaptic function, with a pipeline aimed at neurological and neurodegenerative conditions.
- Who founded Spinogenix?
- Spinogenix was founded by Stella Sarraf, Ph.D., Stella Sarraf in 2016.
- How much funding has Spinogenix raised?
- Spinogenix has disclosed $24.7M raised across 7 rounds.
- Where is Spinogenix headquartered?
- Spinogenix is headquartered in Los Angeles, US.